In vitro activity of OPT-80 against clostridium difcile

被引：83

作者：

Ackermann, G ^{[1
]}

Löffler, B ^{[1
]}

Adler, D ^{[1
]}

Rodloff, AC ^{[1
]}

机构：

[1] Univ Leipzig, Inst Med Microbiol & Epidemiol Infect Dis, D-04103 Leipzig, Germany

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2004年 / 48卷 / 06期

关键词：

D O I：

10.1128/AAC.48.6.2280-2282.2004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 [微生物学]; 100705 [微生物与生化药学];

摘要：

Clostridium difficile remains the major cause of nosocomial diarrhea. Reports on impaired susceptibility of C. difficile to metronidazole and vancomycin and frequent relapses of patients after therapy necessitate the search for new substances. With this study, the activity of OPT-80, a new macrocycle, against 207 C. difficile strains and against other obligately anaerobic bacteria was tested. OPT-80 showed high in vitro activity against all C. difficile strains tested.

引用

页码：2280 / 2282

页数：3

共 12 条

[1]

Reduced susceptibility of Clostridium difficile to metronidazole [J].

Brazier, JS ;

Fawley, W ;

Freeman, J ;

Wilcox, MH .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (05) :741-742

[2]

*DTSCH I NORM, 2000, MED MIKR IMM DIAGN V

[3]

Recurrent Clostridium difficile diarrhea: Characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial [J].

Fekety, R ;

McFarland, LV ;

Surawicz, CM ;

Greenberg, RN ;

Elmer, GW ;

Mulligan, ME .

CLINICAL INFECTIOUS DISEASES, 1997, 24 (03) :324-333

[4]

Antimicrobial susceptibilities of equine isolates of Clostridium difficile and molecular characterization of metronidazole-resistant strains. [J].

Jang, SS ;

Hansen, LM ;

Breher, JE ;

Riley, DA ;

Magdesian, KG ;

Madigan, JE ;

Tang, YJ ;

Silva, J ;

Hirsh, DC .

CLINICAL INFECTIOUS DISEASES, 1997, 25 :S266-S267

[5]

Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile [J].

Kyne, L ;

Hamel, MB ;

Polavaram, R ;

Kelly, CNP .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (03) :346-353

[6]

Recurrent Clostridium difficile disease:: Epidemiology and clinical characteristics [J].

McFarland, LV ;

Surawicz, CM ;

Rubin, M ;

Fekety, R ;

Elmer, GW ;

Greenberg, RN .

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1999, 20 (01) :43-50

[7]

*NAT COMM CLIN LAB, 1997, M11A4 NAT COMM CLIN

[8]

Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin [J].

Peláez, T ;

Alcalá, L ;

Alonso, R ;

Rodríguez-Créixems, M ;

García-Lechuz, JM ;

Bouza, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1647-1650

[9]

LIPIARMYCIN, A NEW ANTIBIOTIC FROM ACTINOPLANES .3. MECHANISM OF ACTION [J].

SERGIO, S ;

PIRALI, G ;

WHITE, R ;

PARENTI, F .

JOURNAL OF ANTIBIOTICS, 1975, 28 (07) :543-549

[10]

INVITRO AND INVIVO EVALUATION OF TIACUMICIN-B AND TIACUMICIN-C AGAINST CLOSTRIDIUM-DIFFICILE [J].

SWANSON, RN ;

HARDY, DJ ;

SHIPKOWITZ, NL ;

HANSON, CW ;

RAMER, NC ;

FERNANDES, PB ;

CLEMENT, JJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) :1108-1111

← 1 2 →